Overview

Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
In the present prospective, multicentric, randomized, double-blind, parallel, saline-controlled phase II clinical study; the investigators plan to evaluate the efficacy of sovateltide (IRL-1620 or PMZ-1620) therapy along with standard supportive care in patients of acute ischemic stroke.
Phase:
Phase 3
Details
Lead Sponsor:
Pharmazz, Inc.